Skip to main content

Day: August 28, 2023

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function Data presented at the International Congress of Parkinson’s Disease and Movement Disorders® Gain remains on track to begin a Phase 1 clinical study of GT-02287 later this year BETHESDA, Md., Aug. 28, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced preclinical data demonstrating the Company’s lead drug candidate GT-02287 significantly decreased Parkinson’s disease (PD)-associated pathology and improved motor dysfunction in two different...

Continue reading

ScottsMiracle-Gro Announces Promotion of Nate Baxter to COO; Mike Lukemire to Remain President Until Retirement in Fiscal 2024

MARYSVILLE, Ohio, Aug. 28, 2023 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the world’s leading marketer of branded consumer lawn and garden as well as indoor and hydroponic growing products, today announced that it is executing a succession plan for President and COO Mike Lukemire in preparation for his retirement in fiscal 2024. Under the plan approved by the Board of Directors and agreed upon by Lukemire and Chairman and CEO Jim Hagedorn, Lukemire will step down as COO on September 3, 2023, and retain his position as president until his retirement. In a related move, Nate Baxter, 50, executive vice president of technology & operations, will be promoted to chief operating officer on September 4, 2023, reporting to Lukemire, who will mentor Baxter during a transition period. Lukemire, 65, has been with...

Continue reading

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year. The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH), will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability. Akero plans to hold an investor webcast detailing the findings. About SYMMETRY...

Continue reading

CLS Americas and Focalyx Co-Marketing Agreement for Image-Guided Focal Laser Ablation of Prostate Tumors Using TRANBERG and Focalyx Fusion Systems

Minimally Invasive, Outpatient Treatment Designed for Quick Recovery and Low Risk of Unwanted ED and UI Side Effects IRVINE, Calif. and MIAMI, Aug. 28, 2023 (GLOBE NEWSWIRE) — CLS Americas, a leading provider of office-based, focal laser ablation systems in the US urology market, and Focalyx® today announced a co-marketing agreement to sell and market their integrated, minimally invasive, fusion-guided focal laser ablation treatment for low-to-intermediate risk prostate cancer patients. CLS’s TRANBERG™ Thermal Therapy System and the Focalyx® Fusion image-guidance system will initially be offered under a Mobile Services Provider (MSP) Agreement that includes consumable accessories, training, and on-site clinical and technical support to physicians and staff during procedures. Focalyx® currently serves centers for diagnosis...

Continue reading

Brunswick Exploration Provides Update on Ontario, Manitoba and Saskatchewan Projects

MONTREAL, Aug. 28, 2023 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW; “BRW” or the “Company”) is pleased to provide an update on all 2023 exploration programs that were completed in the provinces of Ontario, Manitoba and Saskatchewan. Mr. Killian Charles, President and CEO of BRW, commented: “All exploration programs were successful in rapidly testing multiple targets by prospecting, diamond drilling and stripping. Our teams visited the majority of the grassroot targets despite adverse conditions caused by worsening forest fires in Western Canada and the Northwest Territories, constraining the extent of our work. With the recently announced discovery at our Mirage Project and in tandem with the limited exploration success in Central and Western Canada, we have decided to pause all activities in Ontario, Manitoba and...

Continue reading

Nuvei offers APAC’s online traders instant cash-outs via Mastercard Send™

Mastercard Send™ enables secure, real-time* fund transfers for organizations of all sorts in 100+ markets SINGAPORE & MONTREAL, Aug. 28, 2023 (GLOBE NEWSWIRE) — Canadian fintech company Nuvei (Nasdaq: NVEI) (TSX: NVEI) and Mastercard today announced that they will enable near instantaneous payout capabilities for online trading platforms and investors in the Asia Pacific region via Mastercard Send™. Already available to Nuvei customers in Singapore, the Send™ service – which powers rapid payments for merchants, acquirers, governments, consumers and more, wherever they interact worldwide – will also be available in Australia and Hong Kong SAR, starting later this year. Nuvei customers will then be able to process payouts, including business to consumer disbursements, and funding transactions between over...

Continue reading

NorthWest Copper Activist Group Refuses to Address Five Key Shareholder Concerns

Activist Group under scrutiny after NorthWest files application with British Columbia Securities Commission to protect minority shareholders from potential securities laws violations Shareholders urged to Vote Only the BLUE proxy FOR NorthWest’s nominees to protect their investment in the Company Don’t wait. Deadline is fast approaching. BLUE proxies must be received by the proxy voting deadline of 10:00 a.m. (Vancouver time) on September 15th, 2023 in order to be counted at the Annual Meeting For voting assistance or information, shareholders should contact Kingsdale Advisors, at 1-888-518-1565 (toll-free in North America) or 1-647-251-9704 (collect call outside North America) or contactus@kingsdaleadvisors.com and visit www.ProtectNWST.comVANCOUVER, British Columbia, Aug. 28, 2023 (GLOBE NEWSWIRE) — NorthWest Copper Corp....

Continue reading

Woodward Named One of Forbes America’s Best-in-State Employers 2023 in Illinois

Woodward CampusWoodward, founded in Illinois in 1870, maintains a significant presence in Illinois.FORT COLLINS, Colo., Aug. 28, 2023 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ: WWD), a global leader in the design, manufacture, and service of energy conversion and control solutions, has been awarded one of Forbes America’s Best-in-State Employers 2023 for Illinois, in the Aerospace and Defense sector. Woodward, founded in Illinois in 1870, maintains a significant presence in Illinois, with many members working in engineering, manufacturing, testing, services, or business administration roles in Rockford, Loves Park, and Niles. The award is presented by Forbes and Statista Inc., and the list can currently be viewed on the Forbes website. “Woodward is pleased to be recognized on the Forbes list of America’s Best Employers...

Continue reading

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson’s Disease and Movement Disorders®, taking place in Copenhagen, Denmark. “Recent FDA guidance highlights the importance of patient-focused clinical outcome assessments related to treatment effect. Using data from Essential1, we define for the first time what clinically...

Continue reading

Tecnoglass to More than Double Addressable Market with Strategic Entry into Vinyl Windows

– Signs Long-term Supply Agreement with Global Vinyl Frame Manufacturer – – Vinyl Window Product Lines Expected to Start Deliveries in November of 2023 With Orders and Backlog Already in Place, Serving Both Residential and Commercial End Markets – – New Product Line to Go To Market Under the ES Windows Legacy Brand – Miami, FL, Aug. 28, 2023 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading manufacturer of architectural windows, glass and associated aluminum products for the global residential and commercial end markets, today announced its entry into the vinyl window market. This expansion more than doubles the Company’s addressable market and is expected to further solidify its position as an industry leader in architectural windows and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.